CR20210221A - Derivados de azitromicina y roxitromicina como fármacos senolíticos - Google Patents
Derivados de azitromicina y roxitromicina como fármacos senolíticosInfo
- Publication number
- CR20210221A CR20210221A CR20210221A CR20210221A CR20210221A CR 20210221 A CR20210221 A CR 20210221A CR 20210221 A CR20210221 A CR 20210221A CR 20210221 A CR20210221 A CR 20210221A CR 20210221 A CR20210221 A CR 20210221A
- Authority
- CR
- Costa Rica
- Prior art keywords
- azithromycin
- senolytic
- roxithromycin
- activity
- showed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
Esta descripción expone el uso de azitromicina,roxitromicina y teli tromicina, inclusive derivados de los mismos,como fármacos senolíticos. La BrdU se usó para inducir la senescencia en un modelo de líneas de células fibroblastos humanas. También se dan a conocer métodos para seleccionar compuestos por la actividad senolítica. El ensayo de SRB se usó para medir la viabilidad celular a través del contenido de proteínas. Se descubrió que la azitromicina, la roxitromicina y latelitromicina, productos farmacéuticos aprobados clínicamente, son fármacos senolíticos. Sin embargo, el compuesto precursor relacionado estrechamente, eritromicina, no mostró actividad senolítica. La azitromicina indujo considerablemente tanto glicólisis aeróbica como autofagia en fibroblastos humanos, pero mostró efectos bifásicos que incluían sobre las tasas de consumo de oxígeno mitocondrial con actividad inhibitoria a 50 µM y actividad estimuladora a 100 µM. El sistema de ensayo en tiempo real xCELLigenceMR mostró que la azitromicina focaliza preferentemente las células senescentes, eliminando aproximadamente 97% (casi una reducción de 25 veces en las células senescentes).
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862740137P | 2018-10-02 | 2018-10-02 | |
| US201862750559P | 2018-10-25 | 2018-10-25 | |
| US201962788187P | 2019-01-04 | 2019-01-04 | |
| PCT/US2019/054231 WO2020072598A1 (en) | 2018-10-02 | 2019-10-02 | Azithromycin and roxithromycin derivatives as senolytic drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20210221A true CR20210221A (es) | 2021-06-24 |
Family
ID=70054763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20210221A CR20210221A (es) | 2018-10-02 | 2019-10-02 | Derivados de azitromicina y roxitromicina como fármacos senolíticos |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11957700B2 (es) |
| EP (1) | EP3860616A4 (es) |
| JP (1) | JP2022504204A (es) |
| KR (1) | KR20210072026A (es) |
| CN (1) | CN113164504A (es) |
| AU (1) | AU2019353002A1 (es) |
| BR (1) | BR112021006423A2 (es) |
| CA (1) | CA3114888A1 (es) |
| CL (1) | CL2021000825A1 (es) |
| CO (1) | CO2021004427A2 (es) |
| CR (1) | CR20210221A (es) |
| CU (1) | CU20210024A7 (es) |
| DO (1) | DOP2021000056A (es) |
| EC (1) | ECSP21029576A (es) |
| IL (1) | IL281879A (es) |
| MX (1) | MX2021003808A (es) |
| PE (1) | PE20211006A1 (es) |
| PH (1) | PH12021550719A1 (es) |
| SG (1) | SG11202103293UA (es) |
| WO (1) | WO2020072598A1 (es) |
| ZA (1) | ZA202102157B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111971040B (zh) * | 2017-11-24 | 2022-05-27 | 卢内拉生物技术有限公司 | 用于根除癌症干细胞的三苯基鏻衍生物化合物 |
| KR102673862B1 (ko) * | 2021-07-27 | 2024-06-10 | 전남대학교 산학협력단 | Sestrin2를 유전자가 삽입된 재조합 레트로바이러스 벡터를 포함하는 골 질환 예방 또는 치료용 약제학적 조성물 |
| WO2023085787A1 (ko) * | 2021-11-10 | 2023-05-19 | 주식회사 라이프신약 | 노화세포 제거용 조성물 및 이의 용도 |
| WO2023090901A1 (ko) * | 2021-11-18 | 2023-05-25 | 의료법인 성광의료재단 | 기계 학습을 이용한 세포 노화의 마커를 선별하는 방법, 세포 노화 바이오 마커, 및 이를 이용한 세놀리틱 제제를 스크리닝 하는 방법 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20022292A1 (it) | 2002-10-29 | 2004-04-30 | Zambon Spa | 9a-azalidi ad attivita' antiinfiammatoria. |
| US8202843B2 (en) | 2004-02-27 | 2012-06-19 | Rib-X Pharmaceuticals, Inc. | Macrocyclic compounds and methods of making and using the same |
| EP2102226B1 (en) * | 2006-12-12 | 2012-08-22 | ZAMBON S.p.A. | Macrolide compounds endowed with antiinflammatory activity |
| GB0912584D0 (en) * | 2009-07-20 | 2009-08-26 | Ucl Business Plc | Cyclosporin conjugates |
| US9180134B2 (en) * | 2011-08-18 | 2015-11-10 | Ecole Polytechnique Federale De Lausanne (Epel) | Mitochondrial ribosomal proteins as aging regulators |
| US9775855B2 (en) * | 2011-09-14 | 2017-10-03 | Thomas J. Lewis | Compositions comprising macrolide and tetracycline and their uses |
| KR101435717B1 (ko) * | 2012-09-06 | 2014-09-01 | 영남대학교 산학협력단 | 퀘세틴-3-Ｏ-β-Ｄ-글루쿠로니드를 유효성분으로 함유하는 세포 노화 억제용 조성물 |
| WO2016118859A1 (en) * | 2015-01-22 | 2016-07-28 | Board Of Trustees Of The University Of Arkansas | Compositions and methods for selectively depleting senescent cells comprising flip |
| CA3048660A1 (en) * | 2017-01-03 | 2018-07-12 | Bioatla, Llc | Protein therapeutics for treatment of senescent cells |
| CU20190096A7 (es) | 2017-03-15 | 2020-10-20 | Lunella Biotech Inc | Compuestos derivados de 3-metil-3-hidroxi-4-[(n,n-dimetil)amino]-9-[2-(benciloxi)bencil]-1-oxa-9-azaspiro[5,5]undecano substituidos como inhibidores de la función mitocondrial y composiciones farmacéuticas que los contienen |
| WO2018193125A1 (en) * | 2017-04-20 | 2018-10-25 | Novintum Biotechnology Gmbh | Azithromycin derivatives containing a phosphonium ion as anticancer agents |
| US11197872B2 (en) | 2017-04-21 | 2021-12-14 | Lunella Biotech, Inc. | Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs) |
| CA3063450A1 (en) | 2017-05-19 | 2018-11-22 | Lunella Biotech, Inc. | Companion diagnostics for mitochondrial inhibitors |
| CR20190524A (es) | 2017-05-19 | 2020-01-10 | Lunella Biotech Inc | Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas |
| MX2019014806A (es) | 2017-06-26 | 2020-02-10 | Lunella Biotech Inc | Mitocetoscinas: agentes terapeuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en celulas cancerosas. |
| US11497749B2 (en) | 2017-10-24 | 2022-11-15 | Lunella Biotech, Inc. | Mitoflavoscins: targeting flavin-containing enzymes eliminates cancer stem cells (CSCS) by inhibiting mitochondrial respiration |
| CN111971040B (zh) | 2017-11-24 | 2022-05-27 | 卢内拉生物技术有限公司 | 用于根除癌症干细胞的三苯基鏻衍生物化合物 |
| CA3083487A1 (en) | 2017-12-01 | 2019-06-06 | Lunella Biotech, Inc. | Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
| EP3728300A4 (en) | 2017-12-20 | 2021-08-11 | Lunella Biotech, Inc. | TARGETING MITOCHONDRIAL FISSION VIA MDIVI-1 DERIVATIVES |
| AU2019402099A1 (en) | 2018-12-17 | 2021-07-08 | Lunella Biotech, Inc. | Triple combination therapies for anti-aging |
-
2019
- 2019-10-02 PE PE2021000425A patent/PE20211006A1/es unknown
- 2019-10-02 EP EP19869744.3A patent/EP3860616A4/en active Pending
- 2019-10-02 CN CN201980079188.4A patent/CN113164504A/zh active Pending
- 2019-10-02 CA CA3114888A patent/CA3114888A1/en active Pending
- 2019-10-02 CR CR20210221A patent/CR20210221A/es unknown
- 2019-10-02 BR BR112021006423A patent/BR112021006423A2/pt unknown
- 2019-10-02 CU CU2021000024A patent/CU20210024A7/es unknown
- 2019-10-02 WO PCT/US2019/054231 patent/WO2020072598A1/en active Application Filing
- 2019-10-02 SG SG11202103293UA patent/SG11202103293UA/en unknown
- 2019-10-02 KR KR1020217012994A patent/KR20210072026A/ko unknown
- 2019-10-02 US US17/282,212 patent/US11957700B2/en active Active
- 2019-10-02 JP JP2021518508A patent/JP2022504204A/ja active Pending
- 2019-10-02 AU AU2019353002A patent/AU2019353002A1/en active Pending
- 2019-10-02 MX MX2021003808A patent/MX2021003808A/es unknown
-
2021
- 2021-03-29 IL IL281879A patent/IL281879A/en unknown
- 2021-03-30 ZA ZA2021/02157A patent/ZA202102157B/en unknown
- 2021-03-31 PH PH12021550719A patent/PH12021550719A1/en unknown
- 2021-03-31 CL CL2021000825A patent/CL2021000825A1/es unknown
- 2021-03-31 DO DO2021000056A patent/DOP2021000056A/es unknown
- 2021-04-09 CO CONC2021/0004427A patent/CO2021004427A2/es unknown
- 2021-04-26 EC ECSENADI202129576A patent/ECSP21029576A/es unknown
-
2024
- 2024-02-15 US US18/442,204 patent/US20240180944A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CU20210024A7 (es) | 2021-11-04 |
| US20240180944A1 (en) | 2024-06-06 |
| US20210275560A1 (en) | 2021-09-09 |
| BR112021006423A2 (pt) | 2021-07-06 |
| US11957700B2 (en) | 2024-04-16 |
| DOP2021000056A (es) | 2021-06-30 |
| AU2019353002A1 (en) | 2021-05-06 |
| EP3860616A4 (en) | 2022-07-06 |
| JP2022504204A (ja) | 2022-01-13 |
| EP3860616A1 (en) | 2021-08-11 |
| PE20211006A1 (es) | 2021-06-01 |
| ECSP21029576A (es) | 2021-05-31 |
| CA3114888A1 (en) | 2020-04-09 |
| CN113164504A (zh) | 2021-07-23 |
| ZA202102157B (en) | 2022-09-28 |
| CL2021000825A1 (es) | 2021-10-22 |
| KR20210072026A (ko) | 2021-06-16 |
| MX2021003808A (es) | 2021-05-27 |
| CO2021004427A2 (es) | 2021-04-30 |
| SG11202103293UA (en) | 2021-04-29 |
| PH12021550719A1 (en) | 2021-12-06 |
| WO2020072598A1 (en) | 2020-04-09 |
| IL281879A (en) | 2021-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20210221A (es) | Derivados de azitromicina y roxitromicina como fármacos senolíticos | |
| Wang et al. | Glycine stimulates protein synthesis and inhibits oxidative stress in pig small intestinal epithelial cells | |
| Meca et al. | Comparative cytotoxicity study of enniatins A, A1, A2, B, B1, B4 and J3 on Caco-2 cells, Hep-G2 and HT-29 | |
| Baynosa et al. | The effect of hyperbaric oxygen on nitric oxide synthase activity and expression in ischemia-reperfusion injury | |
| Nelson et al. | VX-222/TELAPREVIR IN COMBINATION WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN IN TREATMENTNAïVE GENOTYPE 1 HCV PATIENTS TREATED FOR 12 WEEKS: ZENITH STUDY, SVR12 INTERIM ANALYSIS: LB-14 | |
| Molinaro et al. | D-aspartate activates mGlu receptors coupled to polyphosphoinositide hydrolysis in neonate rat brain slices | |
| Cavalcante et al. | Neuromuscular effects of venoms and crotoxin-like proteins from Crotalus durissus ruruima and Crotalus durissus cumanensis | |
| Rong et al. | Sirt 1 activator attenuates the bleomycin-induced lung fibrosis in mice via inhibiting epithelial-to-mesenchymal transition (EMT). | |
| MXPA05011435A (es) | 5-hidroxiindoles con grupos de n-oxido y su uso como inhibidores de fosfodiesterasa 4. | |
| BRPI0409790A (pt) | 7-azaindóis e seu uso como terapêuticos | |
| Abad | Chemical constituents, antibacterial properties, and cytotoxic activities of Pycnoporus coccineus | |
| 李溱 | Comprehensive Review on “Critical Period Hypothesis” and the Role of Age in Second Language Learning | |
| Kumari | Recurrent pyoderma with Malassezia and hyperadrenocorticism in a dog | |
| 刘航 | Effect and mechanism of cysteine-rich protein 61 on transforming growth factor-β1-activatedrenal fibroblasts | |
| Takizawa et al. | Direct Sensing of Lipopolysaccharide Limits Hematopoietic Stem Cell Selfrenewal Via TLR4-TRIF-ROS-p38 Pathway | |
| Ai-Zhu et al. | Effects of isoquercitrin from Craibiodendron yunnanense on osteogenic differentiation of MC3T3-E1 cells | |
| WO2020163467A3 (en) | Uses of il-40 and methods for detecting il-40 activity | |
| Wei | CCPIT Encourages More Chinese Investors to Go Abroad | |
| Kolesnichenko et al. | Potentiating interaction of ethoxydol and rosuvastatin in an experimental model of Langendorf-isolated rat heart total ischemia-reperfusion | |
| A Esmaial et al. | Study of Cholinesterase Activity in Adult Ewes Treated by the Anthelmintic Drug Levamisole | |
| Karppinen | Search for biologically active compounds in AndoSanTM, a medicinal mushroom extract | |
| Qiong et al. | Influence of MSAA3 protein fragment and modified peptide thereof on the MUC3 expression of HT29 cells | |
| Miglio et al. | Linagliptin decreases the growth of immortalised human podocytes through the SDF-1-CXCR4/CXCR7 axis | |
| Doss et al. | Human hepatocytes as a tool for hepatotoxicity-testing | |
| Sereda et al. | Antioxidant activity of hynalonamyditin |